Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Milton S. Hershey Medical Center
National Cancer Institute (NCI)
Children's National Research Institute
Children's National Research Institute
Taproot Health
National Cancer Institute (NCI)
Emory University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
Children's Hospital Los Angeles
Emory University
Children's Oncology Group
Emory University
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
Wake Forest University Health Sciences
Memorial Sloan Kettering Cancer Center
Rutgers, The State University of New Jersey
City of Hope Medical Center
Valerio Therapeutics
Valerio Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
INSYS Therapeutics Inc
Children's Oncology Group
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
St. Jude Children's Research Hospital